Clinical trial
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy…
NCT00004054 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00004054 |
|---|---|
| Title | Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer |
| Official title | A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin |
| Enrollment | 397 |
| Start date | Jan 1, 2000 |
| Primary completion | Apr 1, 2010 |
| Completion | Nov 1, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 22, 2020 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: